neurodegenerative disease

(redirected from CNS disorders)

neurodegenerative disease

Any of a group of hereditary and sporadic conditions characterised by progressive dysfunction, degeneration and death of specific populations of neurones which are often synaptically interconnected.

Neurodegenerative diseases
Akinetic-rigid
Examples
Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration, multisystem atrophy with striatonigral degeneration.

Clinical findings
Bradykinesia, rigidity.

Location
Substantia nigra, basal ganglia.

Hyperkinetic
Examples
Huntington’s disease, dentatorubropallidoluysial atrophy.

Clinical findings
Choreoathetosis, dystonia.

Location
Basal ganglia.

Ataxic
Examples
Friedrich’s ataxia, spinocerebellar degeneration, dentatorubropallidoluysial atrophy.

Clinical findings
Cerebellar ataxia.

Location
Cerebellum and connecting tracts.

Motor neuron disease
Examples
Amyotrophic lateral sclerosis, spinobulbar muscle atrophy (Kennedy’s disease), spinal muscular atrophy.

Clinical findings
Motor weakness.

Location
Motor system.

Temporoparietal degeneration
Examples
Alzheimer’s disease, dementia with Lewy bodies.

Clinical findings
Memory changes, parietal lobe dysfunction.

Location
Hippocampus, cortical neurons.

Frontotemporal degeneration
Example
Frontotemporal lobar degeneration.

Clinical findings
Apathy, disinhibition, memory changes.

Location
Frontal and temporal cortex.

Multifocal degeneration
Example
Prion disease.

Clinical findings
Variable cortical and subcortical changes.

Location
Cortical, subcortical neurons.

Neurodegenerative disease

A disease in which the nervous system progressively and irreversibly deteriorates.
Mentioned in: Amnesia
References in periodicals archive ?
Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 80 collaborations.
The topics include magnetic resonance imaging as a tools for modeling drug treatment of CNS disorders, small animal imaging as a tool for modeling CNS disorders, positron emission tomography in Alzheimer disease, neuroimaging as a translational tool in animal and human models of schizophrenia, translational neuroimaging for drug discovery and development in autism spectrum disorders, and neuroimaging approaches to understanding depression and identifying novel antidepressants.
BioFocus, the Galapagos' service division, and Ono Pharmaceutical announced that it has inked a new drug discovery agreement, which focuses on CNS disorders.
Depression and schizophrenia had the largest number of trials among CNS disorders, but the number of early-phase trials for each decreased, while the number of earlier stage trials for Alzheimer's disease, multiple sclerosis, sleep disorders and attention-deficit/hyperactivity disorder increased.
The spinal tap was the only method yielding an abnormal result in a significant number of the patients with CNS disorders, Halperin says.
com/research/mv3bdf/global_cns) has announced the addition of the "Global CNS Disorders Drug Pipeline Capsule - 2012" report to their offering.
Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods.
Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.
The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others.
Rexahn currently has three drug candidates in Phase II clinical trials, Archexin[R], Serdaxin[R], and Zoraxel[TM] and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders.
com/research/564c24/endpoints_clinic) has announced the addition of the "Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted" report to their offering.
29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering.